HCPLive Network

Plaque Psoriasis

Researchers report that patients diagnosed with moderate to severe plaque psoriasis who were treated with ixekizumab, an investigational anti-interleukin-17A monoclonal antibody, have maintained a favorable clinical response over a year-long course of treatment.
Researchers compared the effectiveness of biologics approved in Europe for the treatment of plaque psoriasis based on their performance as measured by primary endpoints in clinical trials.
Amgen and AstraZeneca recently announced AMAGINE-2TM, a pivotal, multi-arm Phase 3 clinical trial, met all primary endpoints for brodalumab, an experimental drug designed for moderate to severe plaque psoriasis treatment.
The compound AIN457 (secukinumab) has been granted a unanimous vote of support for approval from the Dermatologic and Ophthalmic Drugs Advisory Committee to the Food and Drug Administration.
Amgen has released positive top-line results from the first of two Phase III studies of ABP 501, its candidate for the treatment of moderate-to-severe plaque psoriasis that is being developed as a biosimilar to adalimumab.
People with more severe cases of psoriasis may be at increased risk of uncontrolled hypertension, according to a study published online Oct. 15 in JAMA Dermatology.
Plaque Psoriasis Upcoming Events
Paris, France
June 11-14, 2014
New York, NY
July 9-12, 2014
Chicago, IL
August 6-10, 2014
Louisville, KY
August 7-9, 2014
Las Vegas, NV
September 12-13, 2014
Sonoma, CA
September 24-27, 2014
Las Vegas, NV
October 16-19, 2014
Dallas, TX
October 24-26, 2014
Boston, MA
November 14-19, 2014
New Orleans, LA
April 27-29, 2015
Plaque Psoriasis Latest News
Plaque Psoriasis Clinical Trials